SecBot SecBot
PRESS-RELEASE ·Filed Mar 5, 2026

BVS

Bioventus, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The stock may re-rate on sustained organic growth, margin improvement, and strong 2026 guidance. Watch for execution on PNS product launch and cash flow conversion. Short interest could compress if momentum continues.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$9.10
T+0 close · Mar 5, 2026 · via day close
Latest settled
−12.86%
T+60 · $7.93
Vs SPY
−24.16%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 5 $9.10entry
  2. T+1 · 9mo ago −7.58%α −6.27% · $8.41
  3. T+5 · 8mo ago −5.49%α −3.26% · $8.60
  4. T+20 · 8mo ago −1.43%α +2.36% · $8.97
  5. T+60 · 6mo ago −12.86%α −24.16% · $7.93
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Bioventus reported strong Q4 and full-year 2025 results with 10.0% organic revenue growth in Q4, GAAP profitability improvement, and raised 2026 guidance projecting 6-7% revenue growth and 7-13% adjusted EPS growth. The company exited a divestiture-impacted year with improved margins and cash flow, signaling operational strength.

Key Financial Metrics

Revenue
$157.9M
+2.8% YoY
Adj. EPS
$0.24
GAAP: $0.21
Guidance
$600M-$610M
raised

Key Facts

  • Q4 revenue: $157.9M, up 2.8% reported, 10.0% organic; driven by double-digit growth in Pain Treatments and Surgical Solutions
  • Q4 GAAP EPS: $0.21 vs. $0.00 in prior year; Non-GAAP EPS: $0.24 vs. $0.26 in prior year
  • Full-year 2025 revenue: $568.1M, down 0.9% reported (due to divestiture), up 7.5% organically
  • Full-year 2025 GAAP EPS: $0.33 vs. loss of $0.56; Adjusted EPS: $0.68, up 21.4% YoY
  • 2026 guidance: Revenue $600M–$610M (~6-7% growth), Adjusted EPS $0.73–$0.77 (~7-13% growth), CFO: $82M–$87M
  • Q4 cash from operations: $38.0M, up 97% YoY; full-year CFO up 92%
  • Reduced debt by $29M in Q4, strengthened balance sheet

Financial Impact

Revenue growth accelerating organically, earnings normalized to profitability, and 2026 guidance implies continued margin expansion. $32M+ increase in annual revenue guidance and ~$0.05 EPS uplift projected.

revenueepscashFlowdebtoperatingMargin

Risk Factors

  • Adjusted EPS declined slightly YoY despite revenue and operating income growth, due to tax headwinds
  • Restorative Therapies segment still under pressure post-divestiture, though EXOGEN showing organic recovery
  • Forward guidance excludes GAAP net income, limiting visibility on full profitability trajectory

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3249987

Track record

18 reports on BVS

Performance horizon

2 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +37.19% at T+60 after the May 8, 2026 report. 3 of 6 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $10.66 Now $10.46 −1.88% settles Feb 11
  2. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $10.61 Now $10.46 −1.41% settles Feb 4
  3. Nov 2, 202614d ago 8-K Neutral 5/10 No price data
  4. Nov 2, 202614d ago Press Release Neutral 5/10 Entry $10.95 Now $10.46 −4.43% settles Feb 1
  5. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $14.65 Now $10.46 −28.60% settles Jan 26
  6. Aug 15, 202613w ago Institutional Cluster Mixed 5/10 Entry $13.88 to $11.02 Now $10.46 −24.64% ▼ −20.64% −17.88% vs SPY
  7. Aug 5, 202614w ago 8-K Bullish 7/10 No price data
  8. Aug 5, 202614w ago Press Release Bullish 7/10 Entry $15.26 to $14.86 Now $10.46 −31.45% ▼ −2.62% −2.81% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Bearish 4/10 Entry $8.68 to $14.07 Now $10.46 −20.51% ▼ −62.10% −57.70% vs SPY
  10. Jun 2, 202623w ago Press Release Bearish 6/10 Entry $8.11 to $13.97 Now $10.46 −28.98% ▼ −72.26% −71.14% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026